Perry Gemma S, Das Mohua, Woon Esther C Y
School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom.
Lab of Precision Oncology and Cancer Evolution, Genome Institute of Singapore, 60 Biopolis Street, Singapore 138672, Singapore.
J Med Chem. 2021 Dec 9;64(23):16974-17003. doi: 10.1021/acs.jmedchem.1c01694. Epub 2021 Nov 18.
The AlkB family of nucleic acid demethylases is currently of intense chemical, biological, and medical interest because of its critical roles in several key cellular processes, including epigenetic gene regulation, RNA metabolism, and DNA repair. Emerging evidence suggests that dysregulation of AlkB demethylases may underlie the pathogenesis of several human diseases, particularly obesity, diabetes, and cancer. Hence there is strong interest in developing selective inhibitors for these enzymes to facilitate their mechanistic and functional studies and to validate their therapeutic potential. Herein we review the remarkable advances made over the past 20 years in AlkB demethylase inhibition research. We discuss the rational design of reported inhibitors, their mode-of-binding, selectivity, cellular activity, and therapeutic opportunities. We further discuss unexplored structural elements of the AlkB subfamilies and propose potential strategies to enable subfamily selectivity. It is hoped that this perspective will inspire novel inhibitor design and advance drug discovery research in this field.
核酸去甲基化酶的AlkB家族目前在化学、生物学和医学领域备受关注,因为它在几个关键的细胞过程中发挥着重要作用,包括表观遗传基因调控、RNA代谢和DNA修复。新出现的证据表明,AlkB去甲基化酶的失调可能是几种人类疾病发病机制的基础,尤其是肥胖、糖尿病和癌症。因此,人们对开发这些酶的选择性抑制剂以促进其机制和功能研究并验证其治疗潜力有着浓厚的兴趣。在此,我们回顾了过去20年中AlkB去甲基化酶抑制研究取得的显著进展。我们讨论了已报道抑制剂的合理设计、它们的结合模式、选择性、细胞活性和治疗机会。我们进一步讨论了AlkB亚家族未被探索的结构元件,并提出了实现亚家族选择性的潜在策略。希望这一观点能够激发新型抑制剂的设计,并推动该领域的药物发现研究。